

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/729,837		12/04/2003	Manne Satyanarayana Reddy	BULK 3.0-033	8513
45776	7590	05/02/2006		EXAM	8513 NER
		ORATORIES, IN RPORATE BLVD	SACKEY, EI	BENEZER O	
SEVENTH				ART UNIT	PAPER NUMBER
BRIDGEWA	ATER, NJ	08807-2862	1626		

DATE MAILED: 05/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

-		Application No.	Applicant(s)			
	· ·	10/729,837	REDDY ET AL.			
	Office Action Summary	Examiner	Art Unit			
		EBENEZER SACKEY	1626			
Period fo	The MAILING DATE of this communication		l l			
	IORTENED STATUTORY PERIOD FOR R	FPLY IS SET TO EXPIRE 1 MC	NTH(S) OR THIRTY (30) DAYS			
WHIC - Exte afte - If NO - Failt Any	CHEVER IS LONGER, FROM THE MAILIN ensions of time may be available under the provisions of 37 Cl r SIX (6) MONTHS from the mailing date of this communication period for reply is specified above, the maximum statutory pure to reply within the set or extended period for reply will, by reply received by the Office later than three months after the led patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNICATED THIS COMMUNICATED THE STATE OF THIS COMMUNICATED THE STATE OF THE ST	ATION. lly be timely filed HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).			
Status						
1)[Responsive to communication(s) filed on					
		This action is non-final.				
3)[Since this application is in condition for all	owance except for formal matte	rs, prosecution as to the merits is			
	closed in accordance with the practice und	der <i>Ex parte Quayle</i> , 1935 C.D.	11, 453 O.G. 213.			
Disposit	ion of Claims					
4)⊠	Claim(s) 1-56 is/are pending in the applica	ation.				
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)[Claim(s) is/are allowed.					
6)□	Claim(s) is/are rejected.					
	Claim(s) is/are objected to.					
8)⊠	Claim(s) 1-56 are subject to restriction and	d/or election requirement.				
Applicat	ion Papers					
9)[The specification is objected to by the Example 1	miner.				
10)[The drawing(s) filed on is/are: a)	accepted or b) objected to by	the Examiner.			
	Applicant may not request that any objection to	the drawing(s) be held in abeyance	e. See 37 CFR 1.85(a).			
	Replacement drawing sheet(s) including the co	prrection is required if the drawing(s) is objected to. See 37 CFR 1.121(d).			
11)	The oath or declaration is objected to by the	e Examiner. Note the attached	Office Action or form PTO-152.			
Priority ı	under 35 U.S.C. § 119					
	Acknowledgment is made of a claim for for All b) Some * c) None of:	eign priority under 35 U.S.C. § 1	19(a)-(d) or (f).			
	1. Certified copies of the priority document	nents have been received				
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the					
	application from the International Bu		Ç			
* 5	See the attached detailed Office action for a	list of the certified copies not re	eceived.			
Attachmen	t(s)					
	e of References Cited (PTO-892)	4) Interview Sur				
2)	e of Draftsperson's Patent Drawing Review (PTO-948 mation Disclosure Statement(s) (PTO-1449 or PTO/St	Paper No(s)/ B/08) 5) Notice of Info	Mail Date imal Patent Application (PTO-152)			
	r No(s)/Mail Date	6) Other:				

Application/Control Number: 10/729,837

Art Unit: 1626

DETAILED ACTION

Claims 1-56 are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-16, and 33-34 are, drawn to an amorphous form of ziprasidone hydrochloride and method of using the compound in treating psychosis, classified in class 544 and 514, in various subclasses.
- II. Claim 17 is, drawn to a process for making ziprasidone hydrochloride, classified in class 544, subclass 279+.
- III. Claims 18-21 are, drawn to a first process for making an amorphous form of ziprasidone hydrochloride, classified in class 544, subclass 279+.
- IV. Claims 22-32 are, drawn to a second process for making an amorphous form of ziprasidone hydrochloride, classified in class 544, subclass 279+.
- V. Claims 35-46 and 56, drawn to crystalline form of ziprasidone and method of treating psychosis using the compound, classified in class 544 and 514, in various subclasses.
- VI. Claims 47-55 are, drawn to a process for preparing crystalline form of ziprsidone and composition containing the crystalline form of ziprasidone, classified in class 544 and 514, in various subclasses.

The inventions are distinct, each from the other because of the following reasons:

Groups I-VI are drawn to distinct processes of preparing ziprasidone in various forms of
the compounds as demonstrated by the different reactive steps, reactants and X-ray

Application/Control Number: 10/729,837

Art Unit: 1626

diffraction patterns. Additionally, the inventions of Groups I-VI are independent and distinct because there is no patentable co-action among the various groups and a reference anticipating one member will not necessarily render another obvious.

Applicants should note that patentability of product by process claims are based on the product and not the process. Thus, claims 33 and 34 have been added to Group I.

In addition, because of the different classes and subclasses and divergent subject matter, in each of the Groups, a serious burden is imposed on the examiner to perform a complete search of the defined areas. Therefore, for the reasons given above, the restriction set forth is proper because it would constitute an undue burden on the examiner to examine all of the inventions in this application.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

A telephone call was made to Robert A. Franks on 04/26/06 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not

Application/Control Number: 10/729,837

Art Unit: 1626

distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to E. Sackey whose telephone number is (571) 272-0704.

The examiner can normally be reached on Monday-Friday from 7:30 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane, can be reached on (571) 272-0699. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is

Art Unit: 1626

(571) 272-1600.

EOS

April 29, 2006

Joseph K. McKane

Supervisory Patent Examiner Art Unit 1626, Group 1600 Technology Center 1